Canonical Hedgehog (HH) signaling leads to the regulation of the GLI code: the sum of all positive an negative functions of all GLI proteins. In humans, the three GLI factors encode context-dependent activities with GLI1 being mostly an activator and GLI3 often a repressor. Modulation of GLI activity occurs at multiple levels, including by co-factors and by direct modification of GLI structure. Surprisin the GLI proteins, and thus the GLI code, is also regulated by multiple inputs beyond HH signaling. In normal development and homeostasis these include a multitude of signaling pathways that regulate pro oncogenes, which boost positive GLI function, as well as tumor suppressors, which restrict positive G activity. In cancer, the acquisition of oncogenic mutations and the loss of tumor suppressors -the oncogenic load -regulates the GLI code toward progressively more activating states. The fine and reversible balance of GLI activating GLI and GLI repressing GLI states is lost in cancer. Here, the acquisition of GLI levels above a given threshold is predicted to lead to advanced malignant stages. I this review we highlight the concepts of the GLI code, the oncogenic load, the context-dependency of action, and different modes of signaling integration such as that of HH and EGF. Targeting the GLI co directly or indirectly promises therapeutic benefits beyond the direct blockade of individual pathways.
Introduction
The molecular dissection of the Hedgehog (Hh)-Gli signal transduction pathway in insects (e.g. vertebrates (e.g. [8] [9] [10] [11] [12] [13] [14] [15] [16] ), has revealed it to be complex and context-dependent with a surprising numbe distinct cellular outputs. Complexity is found at every level of signaling, from multiple ligands with apparently different streng and perhaps different properties, multiple membrane components (e.g., PTCH1 vs. PTCH2), a bagful o intracellular regulators and the existence of three GLI proteins in humans that mediate final genomic responses, to ligand-driven pathway activation. Complexity is also found in the tissue -specific expre of different modulators and in the multiple variations of the canonical pathway found in different spec
We are just beginning to understand the meaning of species-specific differences in Hh signaling but w is clear is that a single-species (e.g., mouse)-centric view is not universally informative. How or why organisms would have evolved multiple Ptc receptors (as in worms) for instance, increase the number Hh ligands or of Gli proteins (as in zebrafish), or constraint HH signaling to primary clia in some spec and tissues is unclear but likely to have important clues to speciation and the evolution of the morphogenetic plan (reviewed in [15] ).
The outputs are numerous since the HH pathway controls aspects of cell proliferation, survival, migrat and stemness. How these are orchestrated over time in developing tissues remains unclear. The GLI proteins also regulate and are regulated by tumor suppressors, such as p53 and this reveals yet another important aspect of HH-GLI signaling: its major role in human cancer (reviewed in [16] ).
But perhaps the most intriguing aspect of this and other pathways is their context-dependency. How is that the same extracellular input can be interpreted differently by responding cells? How is it that recep of a HH ligand can lead to diverse responses in time, space and in different cell types? While the complexity of the pathway makes a complete discussion for a review chapter not feasible, we focus he on the GLI zinc finger transcription factors, which represent the terminal station of the canonical HH signaling path. Whereas other reviews and papers address key aspects of the morphogenetic function o HH ligands (e.g. [17] [18] [19] [20] ) we elect to focus this review on 3 key points of the highly context-dependen nature of the HH-GLI pathway, where the history and the molecular make-up of the receiving cell determines the qualitative and quantitative output and biological effect: 1 -The GLI code; 2 -Regulat of the GLI code by non-HH signals and by the oncogenic load; and 3 -Mechanisms of GLI regulation choosing to do so, here we wish to emphasize the fact that the GLI transcription factors act as key determinants in the interpretation of context-and concentration-dependent canonical HH-GLI signalin development and disease, and that the GLI code is a signaling integration node.
The GLI code
The GLI code model [21, 22] considers the total GLI function as a balance of positive activator (GLI negative repressive (GLI ) activities with GLI1 being mostly a positive transcription factor and GLI3 mostly a transcriptional repressor. The GLI :GLI ratio is thus critical, being highly regulated, specie and context-specific, and highly dynamic (Fig. 1 ).
GLI proteins belong to the superfamily of zinc finger transcription factors with five sequential zinc fin R A R of the C2H2 type constituting the sequence specific DNA binding domain. GLI1 (originally GLI) was identified as an amplified gene in a human glioblastoma cell line [23, 24] . Later on and independently, what turned out to be its fly homolog, Cubitus interruptus (Ci) was identified and placed in the Hh pathway [7, [25] [26] [27] ]. GLI1 was not linked to the vertebrate Hh pathway until later [12, 28] . While the Drosophila genome encodes only one GLI protein, the mouse and human genomes comprise three: GL GLI2 and GLI3.
One of the most remarkable features of GLI proteins is that in canonical HH signaling they can act as transcriptional activators and repressors [29] [30] [31] [32] [33] . The situation is likely to be complex as all GLI prote can act as activators or repressors in a stage-dependent and target gene-dependent manner [34] the basic idea of the GLI code is useful as a framework and generally considers GLI1 as an activator a GLI3 mostly as a repressor.
In the absence of HH pathway activity positive GLI function is off, GLI1 is not transcribed GLI code is tipped toward a GLI output, thus leading to pathway silencing. In this context, GLI2/3 proteins are proteolytically processed into C-terminally truncated repressors consisting of an N-termin repressor domain and the DNA binding zinc fingers, but lacking the C-terminal transactivation domain There is also evidence for GLI1 isoforms but how these are produced is not clear [35] .
GLI processing in the absence of HH signaling is triggered by sequential phosphorylation of Ci or GL by Protein Kinase A (PKA), Glycogen Synthase Kinase 3-beta (GSK3β) and Casein Kinase 1 (CK1) followed by proteasomal degradation of the C-terminal region [31, 33] . Truncated Ci/GLI repressor bin to GLI sites in HH target promoters, thereby shutting off target gene expression (e.g. [37] [38] [39] [16,40])).
Activation of canonical HH signaling abrogates GLI processing allowing full-length and active GLI (GLI ) to enter the nucleus and turn on target gene expression. HH-GLI signaling also has feed-forwa and feedback loops. In the latter case, GLI1 directly regulates PATCHED1 (PTCH1), genetically a SMOOTHENED (SMOH) inhibitor, but it also autoregulates itself. GLI2/3 activity leads to expression, which further positively boosts GLI1 transcription. How his apparently close loop is broke unclear, in order to allow precise and reversible control of the GLI code, which is of utmost importanc proper development and health. It is also unclear how the GLI proteins act since there is evidence that GLI code will be highly refined and meticulously regulated given that GLI1, GLI2 and GLI3 can act in combinatorial manner [30, 34, [41] [42] [43] .
The importance of the critical and tight regulation of the GLI code is illustrated on the one hand by the that varying levels of HH-GLI will induce different numbers of neural stem cells in normal developme and homeostasis [35, [44] [45] [46] [47] [48] , and also induce different cell fates in the ventral neural tube in response t morphogenetic gradient of HH ligands [8, 9, 11, [49] [50] [51] . On the other hand, genetic and/or epigenetic changes leading to irreversible activation of GLI , and GLI1 [52], can drive a variety of malignant sta ranging from cancers of the brain, skin, breast, prostate and digestive tract to malignancies of the hematopoietic system (e.g. [16, [52] [53] [54] [55] [56] [57] [58] [59] [60] ).
Regulation of the GLI code by non-HH signals and by the oncogenic load
The GLI code may be seen as the essential parameter to regulate canonical HH output. Its regulation fi R A A A appeared to be strictly dependent on the presence of specific levels of HH ligands. Indeed, GLI1 transcription is so far the only general biomarker of a cell's response to HH ligands [12] , it can be a diagnostic tool for HH pathway activity [52] and is used to measure the efficiency of SMOH blockers clinical samples [61] [62] [63] .
However, surprising data revealed that the GLI1 code and activity can also be modulated by non-HH signals [64, 65] . Such regulation occurs in normal and in disease contexts and here we highlight key examples (Fig. 2) .
3.1. Tumor suppressors negatively regulate GLI1 activity in normal development and homeostasis.
The first example of tumor suppressors regulating normal GLI activity came from the work on p53, w p53 negatively regulates GLI1 [35] . Interestingly, GLI1 also regulates p53 [35, 66] , thus creating a regulatory loop in which the GLI code is subjected to the precise regulation by p53. Modulation of p53 GLI1 takes place through MDM factors [35, 66] and it remains unclear how p53 represses GLI1 althou involves okadaic acid-sensitive protein phosphatases, possibly PP2A [35].
Loss of tumor suppressors leads to unregulated GLI1 activity.
Loss of p53 is a common occurrence in human tumors and this provokes the unregulated up-modulatio GLI1, thus leading to increased tumor cell proliferation and increased self-renewal of cancer stem cell [35] . Similarly, PTEN negatively regulates GLI1 activity in different human tumors that include melanomas [65] . This activity may flow through the action of AKT, which positively regulates GLI1 ( below) and is itself negatively modulated by PTEN [65, 67] , a repressor of AKT (see below). Many oth tumor suppressors have since been found to regulate GLI. For example, loss of the SNF5 or Menin lea activation of GLI1 [68, 69] .
Oncogenes, and the pathways that normally regulate proto-oncogenes, positively regulate GLI
Not only do common tumor suppressors repress GLI1 but common oncogenes, including RAS, MEK, MYC and AKT, positively regulate GLI1 in different tumor types [65, 70] . Moreover, regulation of [71, 72] and possibly of AKT [73] by GLI1, may establish positive feed-forward loops. Together, this insures that GLI1 activity will increase as tumor suppressors are lost and oncogenes gained. This has l the idea that it is the stepwise gain of oncogenic events and loss of tumor suppressors -named the oncogenic load -that leads to the acquisition of higher and higher GLI1 levels and thus higher and hig levels of GLI [64] . These increases then drive GLI beyond thresholds that induce changes in cell fa and behavior, such as the acquisition of metastatic behavior [64, 70, 71, 74] .
Note that one key contribution to the oncogenic load in a number of cancers, such as basal cell carcino is the oncogenic mutation of the HH-GLI pathway itself, often through loss of PTCH1 in familial tumo [75, 76] , or loss of PTCH1, gain of SMOH activity or increase of SHH levels in sporadic cancers [52, 53, 56, 65, 70, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] .
Interestingly, initial evidence for non-HH signaling regulating the GLI code came from studies with fr embryos where GLI2 was found to act in the FGF-Brachyury loop in the early mesoderm [87] separate study, the growth of mouse brain neurospheres was found to be dependent on both EGF and S HH (SHH) signaling but only after decreasing their levels [46, 47] . This synergism between EGF and S A A
[47], together with the regulation of GLI2 by FGF [87] , and the regulation of GLI1 by RAS-MEK-AK [65] [102] .
Finally, interactions between pathways may be balanced by direct transcription factor binding such as between GLI repressors and SMAD proteins, the latter being the mediators of normal and oncogenic B and TGFβ signaling [103, 104] .
HH and EGF in human basal cell carcinoma
The integration of HH and EGF signaling [46,47,92] has been intensely studied given its development interest and its high therapeutic relevance. Here we describe HH-GLI and EGF crosstalk as one examp of how a cell can integrate apparently parallel signal inputs.
HH and EGF signaling synergistically promote oncogenic transformation and integration of the signal occur at different levels. SHH can transactivate the EGF receptor (EGFR) [105] . In addition, EGF activates the RAS-MEK cascade and this can superactivate GLI1 [65] . Moreover, both pathways can converge on the level of common target gene promoters resulting in selective and synergistic modulati of gene expression (reviewed in [59, 106] In this context, cooperation of EGFR with GLI1 and GLI2 depends on activation of MEK/ERK signal while PI3K/AKT function is dispensable downstream of EGFR. MEK/ERK induced phosphorylation a activation of the JUN/AP1 transcription factor is the critical event at the terminal end of the EGFR cascade, inducing binding of activated JUN and GLI to common HH-EGFR target promoters, thereby cooperatively regulating target gene expression and transformation [92, 93] . It is noteworthy that althou basically all receptor tyrosine (RTK) pathways (e.g., HGF, VEGF or FGF) activate MEK/ERK, this is context-dependent as not all of them synergize with HH-GLI in human keratinocytes, possibly because they fail to activate JUN/AP1 in these cells [90] . So far, only EGFR and PDGFRA [107] signaling hav been identified as being able to stimulate both MEK/ERK and JUN/AP1 and synergize with HH-GLI i basal cell carcinoma (BCC) (Fig. 4) . Importantly, the beneficial effect of EGFR blockade in HH-driven BCC and pancreatic cancer models can be synergistically improved by combined targeting of both pathways [90,93,108].
HH-GLI and WNT-TCF in human colon cancer
A second example involves the interaction between HH and WNT signaling in human colon cancer In this context, enhanced GLl1 represses WNT-TCF targets and repression of WNT-TCF targets via dominant-negative dnTCF leads to enhanced HH-GLI targets [71] . This mutually inhibitory interaction distinct from that seen in other contexts between these two pathways (e.g. [100, 109] ) and is relevant in context of the metastatic transition of human colon cancers. Patients with metastases, but not those without, harbor local intestinal tumors that display repressed WNT-TCF and enhanced HH-GLI pathw as assessed by target gene signatures [71] . This switch, from high WNT-TCF, which drives initial intes tumorigenesis (e.g.
[110]), to low WNT-TCF and enhanced HH-GLI in advanced and metastatic tumor was totally unexpected and is critical as experimental repression of WNT-TCF or enhancement of HH in xenografts leads to increased metastases in mice [70, 71] . Blocking WNT-TCF in advanced cancers thus not recommended.
The interaction between the HH-GLI and WNT-TCF pathways is complex and stage-dependent: TCF activity, essential for βCATENIN activation of WNT-TCF targets, is required for intestinal initiation an for adenomas. (e.g. [111] ). However, while it is also required for advanced human colon cancer cells in vitro [110] it is not required in vivo [71] . Moreover, HH-GLI is dominant: enhanced GLI1 levels, or suppression of PTCH1, rescue the deleterious effects of TCF blockade by dnTCF [71] . There thus app to be a functional cross-pathway switch at the metastatic transition. WNT-TCF may keep tumors in a crypt-like state and enhanced HH-GLI together with repressed WNT-TCF may allow tumors to change and behavior and become metastatic [71] .
Modeling such interactions in mice has revealed that Hh-Gli signaling is a parallel requirement since intestinal tumorigenesis can be initiated by loss of Apc but it is fully rescued by concomitant loss of Sm in the intestine [112, 113] .
Understanding how WNT-TCF and HH-GLI inputs are integrated is of great importance given the essential functions of both pathways in stem cells, human disease and development. Such integration o parallel signaling inputs can take place at multiple levels. In the case of WNT-TCF signaling, there is evidence for binding of βCATENIN, the final output of canonical WNT pathway and both GLI3 C′-terminally deleted repressors and GLI1 [71, 114] . Whether this interaction is the key mode of integration remains to be determined.
Mechanisms of GLI regulation 4.1. Context-dependent regulation of GLI activity by modulation of DNA binding
GLI proteins regulate target gene promoters by binding the consensus sequence GACCACCCA The two cytosines flanking the central adenine in the consensus sequence are essential for binding, wh the other positions allow a certain degree of variation ( Fig. 5A ) [117, 118] . Sequence-specific DNA bin to the cis-regulatory region of a GLI target gene mainly involves zinc fingers 4 and 5 which make extensive base contacts within the 9-mer binding sequence, while fingers 2-3 mainly establish a few contacts with the phosphate backbone. Extensive protein-protein contacts between fingers 1 and 2 apparently contribute to the overall stability of the DNA binding domain [119] (Fig. 5B) . Fingers 1 an also provide protein-protein interaction sites to form GLI2, GLI3 and ZIC2 complexes [34] Although global chromatin immunoprecipitation analyses and in vitro GLI-DNA binding screenings confirmed the consensus sequence as dominant binding site for GLIs [38, 39, 115, 116, 120] , the importa of GLI binding sequences with 1-2 base pair substitutions is underappreciated and therefore possibly neglected or overseen in many studies. Variations of the consensus sequence while preserving function contribute to subtle differences in DNA-protein binding affinity and hence may have a significant imp on the transcriptional output in response to defined GLI activator levels [117, 118, 121] . For instance, substitution of the consensus cytosine at position 7 for adenine results in a GLI binding site with even enhanced transcriptional response compared to the consensus motif [117] .
Variants of the consensus GLI binding site contribute also to selective target gene activation by differe GLI proteins. Although all GLI proteins bind the 9-mer consensus sequence with comparable affinity, repressor and activator forms bind the same sites [37] , and different GLI proteins affect the same targe genes differently [34, 41] . For example, GLI2 induces expression of the direct GLI target BCL2 significantly more strongly than GLI1 and systematic analysis of the BCL2 promoter reveals that one the three validated GLI binding sites accounts for the preferential response to GLI2 [122] .
In line with the documented morphogenetic activity of HH-GLI signaling e.g., in the neural tube (revie in [123, 124] variations in binding site affinity are likely to play a major role in the interpretation of threshold GLI activity levels above which a gene is transcribed or below which the very same gene remains silent. Accordingly, high affinity GLI binding sites in the cis-regulatory region of GLI targets ensure expression at both high and low levels of GLI activator activity, while targets with low affinity binding sites will respond to high GLI activity only, as demonstrated for the response of neural tube patterning genes controlled by GLI [118] . High affinity binding may be generated by GLI binding site sequence variants and/or multiple repeats of the binding motif. This also suggests that not only quantit differences in the absolute GLI protein level or activity determine the context-dependent cellular responses to HH-GLI [50,51,125] but also differential epigenetic modifications of the cis-regulatory regions of GLI targets affecting GLI-DNA binding affinity. Cell-type specific histone acetylations or methylations and/or CpG methylation patterns of GLI target gene promoters are thus likely to modulat both the qualitative and quantitative response to GLI [118] , an area in the HH-GLI field that has not ye been explored in great detail.
Distinct combinatorial GLI function could also account for the substantial difference and contextdependency of GLI1 regulated gene networks in the early embryo [30, 34, 41] , as well as in the normal developing cerebellum and in medulloblastoma [120] . A genome-wide survey of GLI1 binding locatio A revealed numerous GLI1 binding sites in both the normal and malignant tissues, though the location an expression pattern diverged significantly between normal and malignant cells [120] .
Although global ChIP approaches successfully and reliably identified classical HH-targets in addition novel targets, it should be noted that these studies were performed with epitope tagged and overexpres GLI [38, 39, 118, 120] , which may fully mimic endogenous GLI function. It is therefore possible that fu approaches will refine our current understanding of context-dependent target gene regulation, once rel and high-quality antibodies suitable for the isolation of rare endogenous GLI proteins bound to DNA become available.
Context-specificity of the GLI code by interactions with co-factors
Specificity and activity of transcription factors (TF) heavily depend on interactions with activating or repressing co-factors as well as on co-occurrence of other TF that can bind and/or act cooperatively to regulate target gene expression (Fig. 5C ). It follows that the absence or presence of GLI co-factors or cooperative transcription factors within a given cellular context is a major determinant of the transcriptional output.
An example of such an interplay with cofactors that regulates the GLI code is the functional interactio between Zic and Gli proteins [126] (Fig. 3) . The Zic factors are nuclear proteins with a GLI-type 5 zin finger domain [127] that can recognize GLI binding sites albeit with different affinities [128] modify GLI outputs [126, 128] and can interact through the first two zinc fingers [34, 129] . In the early neural plate of frog embryos, Zic2 is expressed in specific longitudinal bands that are adjacent to zone primary neurogenesis, which is triggered by GLI proteins expressed throughout the plate. The overlap leads to the repression of Gli proneurogenic function by Zic2 in restricted domains, thus leading to the definition of domains of neurogenic differentiation [126] . In this context, Zic2 mimics C-terminally truncated Gli repressors [126] . In a different context Zic2 may mimic positive GLI function as it is required for ventral forebrain fates: Loss of ZIC2 is associated with human holoprosencephaly paralleling the association of this malformation with loss of SHH [131] or GLI2 [132] .
A second case that exemplifies a different form of interaction is the cross-functional network of GLI1, and NANOG (made from NANOG1 and NANOGP8 in human cancer cells) (Fig. 3) . As discussed abov p53 negatively regulates GLI1 [35] and GLI1 negatively regulates p53 [35, 66] . p53 would appear to b active in most cells. However, a further layer of regulation is provided by the homeodomain and stemn factor NANOG, which forms a positive feed-forward loop with GLI1 [133] . Interestingly, this loop is regulated negatively by p53, establishing a highly dynamic node that will be affected by any input that affect GLI1, NANOG and/or p53 [133] (Fig. 3) . Regulatory mechanisms involve regulation of MDM proteins by GLI1, protein phosphatase action, direct GLI regulation of NANOG1 expression and the ac of microRNAs [35, 66, 134, 135] . Thus, in adult cells expressing NANOG, likely stem cells and cancer cells, the GLI code will be modulated by additional positive mechanisms. As p53 is often lost in cance this is predicted to free the GLI1-NANOG loop from negative regulation, allowing unrestricted activit GLI . The essential role of NANOG and HH-GLI is demonstrated by their regulation of clonogenic gliomaspheres and by their absolute requirement for the growth of primary human glioblastomas orthotopically engrafted in the brains of host mice [133] .
A Additional mechanisms of GLI code regulation include interactions with CREB-binding protein (CBP Genetic and functional studies first carried out in the fruit fly and later in mammalian cells have identi CBP as essential co-factor for Ci and GLI3 mediated target gene activation [136] . Haploinsufficiency CBP is associated with Rubinstein-Taybi syndrome, a genetic disorder characterized by several developmental anomalies with partially striking similarities to defects observed in patients suffering fr Greig's cephalopolysyndactyly syndrome, which is caused by mutations in the GLI3 gene [136] [137] [138] [139] Given the intrinsic histone acetyl transferase (HAT) of CBP/p300 [140] , CBP-GLI interactions are like to cause epigenetic changes of the cis-regulatory region of GLI targets making them more accessible to other transcriptional regulators. In line with this hypothesis, histone acetyl transferase PCAF interacts GLI1 and enhances HH-GLI target gene expression in medulloblastoma cells by promoting the level o H3K lysine modifications [141] . However, when functioning as ubiquitin ligase, PCAF can also negat regulate GLI activity under genotoxic stress conditions [142] .
Further evidence for epigenetic modifications in context-dependent GLI activity comes from studies o SAP18, a component of the histone deacetylase complex. Recruitment of SAP18 to GLI via binding to negative GLI regulator Suppressor of Fused (SUFU) [143] is crucial for efficient repression of GLI tar genes [144, 145] . Like SAP18, Atrophin (Atro) has been identified in fish and flies as a GLI/Ci cofacto required for target gene repression via recruitment of histone deacetylases [146] .
TBP-associated factor 9 (TAF9) encodes a transcriptional co-activator that directly interacts with the G activator forms GLI1 and GLI2 via their transcriptional activation domain [147] . TAF9 has been show enhance the transcriptional activity of GLI, which may play an oncogenic role in lung cancer. Both gen and chemical inhibition of TAF9-GLI interactions dampen GLI target gene transcription, thus providin possible therapeutic strategy to target oncogenic HH-GLI signaling downstream of the common HH dr target SMOH [147] .
Furthermore, direct interaction of GLI3 with MED12, a subunit of the RNA Polymerase II transcriptio Mediator, enhances the transcriptional response to GLI activator by reversing the Mediator-regulated repression of HH target genes [148] .
Transcriptional activity of GLI proteins can be negatively regulated by binding to cofactors including 14-3-3 protein. Notably, PKA phosphorylation at amino acid residues distinct from those enhancing G repressor formation promote association of 14-3-3 with GLI2 and GLI3, thereby repressing their transcriptional activity independent of the intrinsic N-terminal repressor domain of GLI2 and GLI3
Studies addressing selected GLI target gene promoters together with global approaches analyzing the entire landscape of GLI target gene promoters revealed the importance of combinatorial transcription factor binding in context-dependent HH-GLI target gene regulation (Fig. 5C ). For instance, high level activation of a subgroup of direct GLI target genes such as IL1R2, JUN/AP1, or ARC was abolished b inhibition of JUN expression as full transcriptional activation of these targets is likely to require co-occupancy of their promoter region by GLI and JUN/AP1, similar to the mechanism accounting for and EGF signal integration [90, 93, 150] .
Another example of how combinatorial binding of transcription factors controls context-dependent HH output is illustrated by the finding that co-occupancy of selected GLI targets by GLI1 and SOX2 is required for full activation of a neural gene expression signature [118] .
Motif enrichment analyses identified E-box sequences as frequently co-occurring with GLI binding sit GLI target genes expressed in medulloblastoma [120] . It is therefore possible, that E-box binding bHL transcription factors cooperate with GLI in the control of tissue specific target gene expression and can development, a model that still needs to be confirmed in future studies.
Modulation of GLI DNA binding affinity and transcriptional activity by post-translational modifications
Fine-tuning and reversible activation/termination of HH-GLI signaling is critical to proper developme and health. As outlined in the introduction of this article, numerous reports have provided a wealth of showing that precise control of HH-GLI signal strength occurs at nearly every level of the canonical H cascade, ranging from the control of ligand production and ligand-receptor interactions down to the numerous molecular interactions and modifications of GLI proteins eventually determining the molecu phenotype by controlling gene expression in response to pathway activity [20, 22, 40, 54, 151] At the level of GLI code, a number of post-translational modifications of GLI proteins play a fundame role in its control by affecting GLI stability, subcellular localization and DNA binding ability (reviewed in [20, 40] ). To remain focused on the topic of context-dependent GLI activity, we concentra here on GLI modifications that directly affect the intrinsic GLI transcriptional activity.
Post-translational modifications of GLI proteins result in drastic modifications of activity. For instance phosphorylation and acetylation of GLI1/2 at specific amino acid residues have a major impact on the ability of GLI proteins to regulate target genes by modifying their binding to target promoters (see [156] [157] [158] .
Atypical Protein Kinase Cι/λ (aPKC) has been identified as both a HH-GLI target gene and major regulator of GLI activity in basal cell carcinoma. aPKC acts downstream of the essential HH effector a drug target SMOH by phosphorylating GLI1 at amino acid residues located in the zinc finger DNA binding domain. GLI1 phosphorylated by aPKC displays enhanced DNA binding and maximum transcriptional activity. Of note, hyperactivation of aPKC in BCC can account for SMOH inhibitor resistance, rendering it a promising drug target for the treatment of cancer patients unresponsive to classical HH pathway inhibitors targeting SMOH [156] . aPKC (also referred to as PRKCI) can affect HH-GLI signaling also by phosphorylating the transcription factor SOX2. Phospho-SOX2 acts a poten transcriptional activator of HH acetyltransferase expression, leading to increased HH ligand productio and cell-autonomous HH-GLI activation in lung squamous cell carcinoma [159] .
In addition to aPKC phosphorylation of GLI1, several serine and threonine residues in the N-terminal region of GLI1/2 serve as phosphorylation sites involved in GLI activation. In esophageal cancer cells activation of mTOR/S6K1 signaling leads to S6K1-mediated phosphorylation of Ser85 in GLI1, enhan GLI1 transcriptional activity by disrupting its interaction with the negative GLI regulator SUFU note, the S6K1 phosphorylation site at Ser85 of GLI1 is located in a D-site motif that serves as MAP kinase binding site required for phosphorylation and activation of GLI1 by JNK and ERK [160] S6K1 phosphorylation may therefore not only interfere with SUFU binding but also modify GLI phosphorylation by MAP kinases.
A cluster of non-consensus PKA phosphorylation sites (ncPKA) in close proximity to the SUFU bindi site has also been shown to regulate GLI2/3 activation, though the GLI activating kinase responsible fo phosphorylating ncPKA sites has not been identified [161] . Whether phosphorylation of ncPKA sites activates GLI2/3 by disrupting the SUFU-GLI complex or by a different mode also needs to be addres in future studies.
A number of distinct phosphorylation events in the N-terminal region of GLI control full GLI suggests that the N-terminus of GLI proteins serves as integration domain for multiple signals from distinct pathways such as PI3K/AKT, mTOR/S6K or FGF/MEK/ERK signaling [65, 98, 162] an integration function of the N-terminal region, deletion of the GLI1 N-terminus abolishes its ectopic activation of FoxA2 (HNF3β) in the neural tube [30] and its hyperactivation in response to FGF treatm [162] . It follows that this integration domain plays a major role in the fine-tuning of GLI activity in no tissues and importantly, also in the irreversible activation of GLI in cancer cells.
Besides phosphorylation, acetylation of GLI is another parameter in the complex regulation of GLI transcriptional activity. Acetylation of GLI2 at Lys757 by the histone acetyl transferase p300 is a critic negative regulatory modification in HH signaling [157] . Interestingly, acetylated GLI2 displays significantly reduced recruitment to chromatin and consequently only weak activator potential the acetylation site is C-terminal of the DNA binding domain it is unlikely that acetylation directly aff DNA binding affinity. Rather, deacetylation may favor the interaction of GLI with chromatin bound proteins and therefore enhance its recruitment to target gene enhancers/promoters. Indeed, HH signalin promotes deacetylation of GLI1/2 via inducing class I histone deacetylases (HDAC), which has been identified as important step in the activation of GLI target gene expression [157, 158] .
In summary, the remarkable progress in our understanding of GLI modifications highlights contextdependent reversible post-translational modifications as critical determinants of GLI activity. Here, selected kinases (MAPK, S6K1 and aPKC) and deacetylases (HDAC) act as positive regulators, while acetylases (p300), PKA [161] and as yet unidentified phosphatases control the termination of HH sign via GLI inactivation (Fig. 6 ). In cancer a number of these components are deregulated, thus contributin the oncogenic load that regulate the GLI code.
Outlook
Whereas great progress has been made to understand how the GLI proteins act (e.g., reviewed in [7, 21, 58, 59, 64, 163] ), much remains to be understood. For example, it is not clear what are effective endogenous concentrations of GLI proteins, how they interact with co-factors, how can they be modifi in cells receiving simultaneous inputs, how their activity can be affected by and affect epigenetic chan how they are protected from cleavage or modification, or even how the pathway is effectively turned o when required.
Documenting the full range of inputs and factors that can modulate their activities in multiple developmental, homeostatic and disease contexts will require much effort but will certainly be a good Such knowledge may allow us to begin to understand the logic of signaling in development, in disease hopefully also in evolution. Thus, we promote the idea that these analyses must be carried out in all possible species and cell types in order to compare and contrast mechanisms and outcomes in a quest t extract essential signaling principles as well as specific solutions for each system.
A more anthropocentric goal is to understand how the GLI code is perverted in human disease, and specifically in cancer, through pathway corruption and the oncogenic load. Such knowledge will possi lead us to design novel and more efficient therapies against multiple forms of deadly cancers, includin those of the brain, intestine, lung, skin, pancreas and other organs. Indeed, the involvement of HH-GL signaling in normal stem cell lineages and in cancer stem cells [54] raises the possibility that novel molecular approaches to block positive GLI function, reverting the GLI code, could be highly benefici
For example, the discovery of aPKC, PI3K/AKT, mTOR/S6K or EGF signaling (see above) as part of oncogenic load and, importantly, as druggable GLI modulators has already pointed out possible ways o how to design novel combination treatments with improved therapeutic benefit [64, 65, 90, 98, 164, 165] However, despite the increasing number of studies of GLI regulation in health and disease, we are only beginning to realize the remarkable complexity of context-dependent regulatory processes affecting th GLI code. The identification and in depth analysis of modifiers of the GLI code will guide us to the development of better rational combination treatments by synergistically targeting the core of the HHpathway itself, and its modifiers. This will also open therapeutic opportunities to tackle the problem of relapse and drug resistance, as exemplified by the successful targeting of aPKC in SMOH inhibitorresistant basal cell carcinomas [156] .
We are now entering an era where the GLI transcription factors and their modulators are beginning to center stage as drug targets. Targeting transcription factors for cancer therapy has long been considered effective, but clearly the number of recent examples such as those mentioned above along with the identification of small molecule GLI antagonists [166, 167] provide ample proof-of-concept for the therapeutic relevance of such an approach. Given the essential function of GLIs in normal and maligna stem cells, the systematic identification and functional analysis of GLI modulators, particularly of thos amenable to small molecule targeting, as well as studies addressing their context-dependent activity w an area of intense future research with significant impact on several medical areas such as cancer, tissu regeneration and wound healing.
metazoa. Nat Rev Genet. Model for the GLI code and its morphogenetic activity leading to the creation of context-dependent diversity. A grad of HH ligands is interpreted, canonically, by a combinatorial and context-specific distribution of repressor and activa activities of the three GLI proteins, the GLI code. Note that GLI1 and GLI2 have strong activating action and GLI3 i strong repressor in many contexts. Combinatorial GLI activities are then modified by positive or negative modifiers leading to differential regulation of target genes, which may either respond to create graded levels of expression of specific genes or induce specific genes in given thresholds. The output of these genetic changes is then the creation o spatially and/or temporally distinct outputs and behaviors.
Fig. 2
Control of the GLI code by the oncogenic load. (A) Under normal homeostatic conditions a fine-tuned balance of HH signaling as well as of parallel proto-oncogenic (e.g., EGF, FGF, PDGF, etc.) and tumor-suppressive pathways leads precisely controlled levels of GLI /GLI . The balance can be tipped one way or another, thus allowing for the highly controlled ON-OFF switch. For simplicity, feed-forward and feedback regulatory loops are not included. (B) In cance the loss of tumor suppressors and the presence of mutant oncogenes lead to the massive deregulation of the GLI code to a constitutively active ON state (GLI ). Note that given the stable genetic changes resulting from gene mutation, t GLI code is no longer under homeostatic control.
A R A 29 of 36 24/11/14 14:30 Post-translational modifications regulate GLI transcriptional activity. Fine-tuning of GLI activity by phosphorylation/dephosphorylation and acetylation/deacetylation. Left: fully activated GLI transcription factor with multiple phosphorylated serine/threonine residues in the N-terminal region and the DNA binding domain. In addition de-acetylation promotes DNA binding affinity and transcriptional activity, respectively. Several kinases (MAPK, S6K aPKC) and deacetylases catalyze the activation of GLI, while phosphatases, PKA and acetyltransferases negatively regulate GLI activity. Note that PKA phosphorylation of the two amino acid residues C-terminal of the DNA binding domain negatively regulates the transcriptional activity of GLI without affecting processing or stability [161] non-consensus PKA phosphorylation sites involved in GLI activation.
